COMMUNIQUÉS West-GlobeNewswire

LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment
06/10/2026
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that [...]
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
06/10/2026
CALGARY, Alberta, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF) , and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug [...]
Nox Peptides Announces Launch of GHK-Cu and Wolverine Stack for Canadian Research Market
06/10/2026
TORONTO, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Nox Peptides today announced the launch of two research-focused peptide products, GHK-Cu and the Wolverine Stack , expanding its product offering for Canadian laboratories, [...]
Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy
06/10/2026
Peer-Reviewed Paper Introduces QRX003 and Its Mechanism of Action in Netherton Syndrome Case Report Details Professor Alan Irvine’s Clinical Experience Treating a Pediatric Patient Under Quoin’s Compassionate Use [...]
First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)
06/10/2026
First doses of Pixclara administered in Cleveland (OH) and Indianapolis (IN) marking the start of U.S. commercial availability. Pixclara is the only FDA-approved radiopharmaceutical imaging drug for glioma (brain cancer [...]
MediciNova to Participate in the Maxim Growth Summit
06/10/2026
LA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
Smith+Nephew’s revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal
06/10/2026
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that its innovative CARTIHEAL AGILI-C Cartilage Repair Implant is now commercially available in Europe. The CARTIHEAL Implant will [...]
Smith+Nephew lancia in Europa CARTIHEAL™ AGILI-C™, l’innovativo impianto per la riparazione della cartilagine, che sarà presentato all’ICRS Summit in Portogallo.
06/10/2026
Smith+Nephew (LSE: SN, NYSE: SNN) azienda di tecnologia medica, annuncia il lancio commerciale in Europa di CARTIHEAL AGILI-C, l’innovativo impianto per la riparazione della cartilagine. La tecnologia sarà presentata [...]
Transactions in connection with share buy-back program
06/10/2026
Company announcement no. 38 - 26 06 October 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Smith+Nephew lanza en Europa el innovador implante de reparación de cartílago CARTIHEAL™ AGILI-C™, que será protagonista en el Congreso ICRS de Portugal
06/10/2026
Smith+Nephew (LSE: SN, NYSE: SNN), compañía global de tecnología médica, anuncia hoy que su innovador implante de reparación de cartílago CARTIHEAL AGILI-C ya está disponible para su comercialización en Europa. El [...]
Resolution Therapeutics to present interim Phase I/II EMERALD study data on RTX001 as a late-breaker at AASLD 2026
06/10/2026
Interim data from Phase I/II EMERALD study for RTX001, Resolution’s engineered Regenerative Macrophage Therapy, accepted as late-breaking presentation Dr. Lara Campana to present preclinical data on intravenous [...]
Angelini Ventures and EIB Co-lead $58 Million Series A Financing in Rouge Therapeutics to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia
06/10/2026
Marks the fourth investment completed under Angelini Ventures’ €150 million co-investment partnership with the European Investment Bank in less than 12 months Regina Hodits from Angelini Ventures to join Rouge [...]
RQ Bio Appoints Gavin Koh as Chief Medical Officer and Strengthens Leadership to Advance RQB01
06/10/2026
Dr Koh brings extensive infectious disease and clinical development expertise as RQ Bio prepares to advance RQB01 into the clinic Senior appointments across CMC, clinical operations and programme management further [...]
Rewind Therapeutics Secures Additional Financing to Advance Oral GPR17 Remyelination Program
06/10/2026
Financing will be used to advance Rewind's lead oral program designed to promote remyelination and restore neurological function Peer-reviewed data published in PLOS ONE demonstrated remyelination and functional [...]
RougeTx Launches with $58 Million Series A Financing to Advance First-in-Class Treatment for Hereditary Hemorrhagic Telangiectasia
06/10/2026
Series A co-led by BioGeneration Ventures, Angelini Ventures and Kurma Partners, with participation from Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest and Kerna Ventures. Financing will [...]
One04 Therapeutics to present late-breaking interim Phase 1 results for CPV-104 in C3 glomerulopathy at ASN Kidney Week followed by Virtual KOL Event
06/10/2026
First clinical data for CPV-104 in patients, including interim safety, tolerability and pharmacokinetics, accepted as a late-breaking poster Expert panel to join One04 management in a virtual key opinion leader (KOL) [...]
Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market
06/10/2026
ORION CORPORATION PRESS RELEASE 6 OCTOBER 2026 at 9.00 EEST Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market Orion Corporation (“Orion Pharma”) and Qilu Pharma [...]
Bulk Peptides: Kylo Peptides Launches Bulk Research Program for High-Volume Laboratories
06/10/2026
Sheridan, Wyoming, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides [ https://kylopeptides.com/ ] has introduced a research program that supplies bulk peptides to laboratories with higher-volume peptide requirements. It [...]
Kylo Peptides Review Brings Transparency to the Research Peptide Market
06/10/2026
Review highlights testing documentation, lot-specific COAs, independent laboratory analysis, and supplier information to help researchers evaluate research peptide sources. Sheridan, Wyoming, Oct. 06, 2026 (GLOBE [...]

Pages